$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Semaglutide Eased Eating Disorder Symptoms In Penn Trial

In a 60-week randomized trial of 120 adults at the University of Pennsylvania, semaglutide 2.4 mg cut weight by about 15 percent against 3 percent on placebo and improved loss-of-control eating, body image, and eating disorder symptoms.

TML Health DeskNov 18, 4:30 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

Wegovy (semaglutide) dose boxes stacked in a pharmacy (archive). Photo: Nelson R. de Lima Filho, CC BY 4.0, via Wikimedia Commons.
Summary

The Penn team says larger studies come next, and clinicians are told to keep monitoring patients with an eating disorder history while semaglutide treatment runs.

Tap a passage. React to the part that matters.

A medication that quiets appetite might stir disordered eating in vulnerable people. That worry has followed semaglutide since the prescriptions took off. A randomized, placebo-controlled trial from the University of Pennsylvania, published in the International Journal of Eating Disorders, tested the question directly in 120 adults seeking obesity treatment, and the symptoms it tracked mostly moved the other way.

Participants had a body mass index above 27, and they received either semaglutide at 2.4 mg or a placebo for 60 weeks. Both groups got structured lifestyle intervention with dietary counseling and physical activity guidance. The semaglutide group lost about 15 percent of body weight against about 3 percent on placebo, and the drug group also showed greater improvements in loss-of-control eating, eating disorder psychopathology, weight and shape concerns, and body dissatisfaction.

Clinicians will read the binge-eating results first. Among participants who entered the trial with binge episodes or full or subthreshold binge-eating disorder, those on semaglutide were more likely to reach remission or abstinence from binge episodes by the end of treatment. First author Kelly Costello Allison, director of the Penn Center for Weight and Eating Disorders, presented the findings at ObesityWeek 2026 in Washington, D.C.

"Eating disorders and obesity are complex, interrelated conditions that often occur together," Allison said. "These findings suggest that semaglutide may help people not only lose weight, but also improve the psychological and behavioral symptoms that can make weight management so difficult." Senior author Jena Tronieri said the data challenge the assumption that weight loss treatment worsens eating disorder risk.

The authors wrote the caveats into the results themselves. A small number of participants did experience disordered eating behaviors during treatment, and new or worsening symptoms were uncommon in both groups. Monitoring still matters, the authors say, especially for patients with a history of eating disorders, and a 120-person trial at one center needs larger studies behind it before the findings guide routine practice.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.